ONCBeiGeneFinished
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
Advanced Hepatocellular Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 94 (final count)
- Started
- Aug 20, 2021
- Main results expected
- Feb 1, 2024
- Fully finished
- Feb 1, 2024
- Results posted
- Feb 24, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) as Assessed by the Investigator
Measured over: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04948697 · record last updated 2025-02-24 · checked 2026-11-09 15:47 UTC